ESMO 2019: Results from SORCE clinical trial with adjuvant sorafenib
Results from the SORCE clinical trial to assess sorfenib as [...]
Sorafenib versus observation following surgery for metastatic kidney cancer
A potential treatment for a selected group of patients with [...]
Tivozanib in heavily pre-treated advanced kidney cancer patients
Further data from the TIVO-3 clinical trial comparing tivozanib with [...]
ASCO GU 2019: Tivozanib effective for refractory metastatic kidney cancer
The results from the following study were presented at the [...]
Potential biomarkers may predict response to TKIs in metastatic kidney cancer
A recent study published in Clinical Cancer Research and conducted in [...]
Adjuvant therapy with TKIs has no benefit for high-risk kidney cancer
According to the results of a recent meta-analysis of three [...]
Status of adjuvant therapy for the treatment of kidney cancer
Dr Naomi Haas from Abramson Cancer Centre, Philadelphia, presented an [...]
Tyrosine kinase inhibitors for kidney cancer: Past, present and future
In his keynote lecture at the American Society for Clinical Oncology Genitourinary [...]
Adjuvant therapy for renal cell carcinoma
The following article is a good review of the data [...]
Neoadjuvant and adjuvant therapy for renal cell carcinoma: critique, current trials and future directions
The following articles discuss the use of neoadjuvant therapy (drug [...]
